Veru Inc. (NASDAQ:VERU - Get Free Report)'s share price passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.61 and traded as low as $0.58. Veru shares last traded at $0.60, with a volume of 1,264,171 shares changing hands.
Veru Stock Up 3.1%
The company has a market capitalization of $91.32 million, a P/E ratio of -2.56 and a beta of -0.80. The business has a fifty day moving average price of $0.55 and a 200 day moving average price of $0.60.
Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Veru had a negative return on equity of 128.51% and a negative net margin of 223.85%. As a group, equities analysts forecast that Veru Inc. will post -0.22 earnings per share for the current year.
Institutional Investors Weigh In On Veru
Several hedge funds and other institutional investors have recently added to or reduced their stakes in VERU. Oppenheimer & Co. Inc. grew its holdings in shares of Veru by 181.6% in the 4th quarter. Oppenheimer & Co. Inc. now owns 1,120,586 shares of the company's stock valued at $729,000 after acquiring an additional 722,644 shares in the last quarter. MPM Bioimpact LLC bought a new position in Veru in the fourth quarter valued at approximately $2,788,000. Wells Fargo & Company MN increased its position in shares of Veru by 37.1% during the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company's stock worth $49,000 after purchasing an additional 20,430 shares during the last quarter. Barclays PLC raised its stake in shares of Veru by 11.8% during the 4th quarter. Barclays PLC now owns 206,515 shares of the company's stock worth $134,000 after purchasing an additional 21,738 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Veru by 26.1% during the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after purchasing an additional 19,724 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.
About Veru
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
See Also
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
